JPMorgan Starts BioNTech (BNTX) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
BofA/Merrill Lynch Starts BioNTech (BNTX) at Buy
November 4, 2019 6:15 AM ESTBofA/Merrill Lynch initiates coverage on BioNTech (NASDAQ: BNTX) with a Buy rating and a price target of $21.00.
For an analyst ratings summary and ratings history on BioNTech click here. For more ratings news on BioNTech click here.
Shares of BioNTech closed at $16.91 yesterday.
... MoreCanaccord Genuity Starts BioNTech (BNTX) at Buy
November 4, 2019 5:12 AM ESTCanaccord Genuity analyst Arlinda Lee initiates coverage on BioNTech (NASDAQ: BNTX) with a Buy rating and a price target of $22.00.
For an analyst ratings summary and ratings history on BioNTech click here. For more ratings news on BioNTech click here.
Shares of BioNTech closed at $17.01 yesterday.
... More


